+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Fabry Disease Treatment Market by Treatment Type, Disease Domain, Patient Age Group, End-user, Diagnosis and Screening Technology, Treatment Route, Cost Analysis - Global Forecast 2025-2030- Product Image
Fabry Disease Treatment Market by Treatment Type, Disease Domain, Patient Age Group, End-user, Diagnosis and Screening Technology, Treatment Route, Cost Analysis - Global Forecast 2025-2030- Product Image
Sale

Fabry Disease Treatment Market by Treatment Type, Disease Domain, Patient Age Group, End-user, Diagnosis and Screening Technology, Treatment Route, Cost Analysis - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 182 Pages
  • November 2024
  • Region: Global
  • 360iResearch™
  • ID: 4989675
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Fabry Disease Treatment Market grew from USD 2.50 billion in 2023 to USD 2.71 billion in 2024. It is expected to continue growing at a CAGR of 8.47%, reaching USD 4.41 billion by 2030.

The market for Fabry Disease treatment encompasses a wide range of therapeutic solutions aimed at managing and alleviating symptoms of this rare genetic disorder. It includes enzyme replacement therapies, gene therapies, chaperone treatments, and substrate reduction therapies, each addressing different aspects of the disease pathology. The necessity of this market is underscored by the critical nature of Fabry Disease, which can result in life-threatening complications if untreated. Its application is predominantly in the healthcare sector, impacting genetic and rare disease specialists, hospitals, and specialty clinics. End-users are primarily healthcare practitioners, patients, and researchers in genetic disorders.

Market growth is driven by increased awareness and diagnosis rates of Fabry Disease, advances in biotechnology leading to more effective therapies, and ongoing clinical trials potentially expanding the range of available treatments. Opportunities abound in the development of next-generation gene therapies and personalized medicine approaches, with a strong focus on optimizing patient outcomes and minimizing side effects. Strategic partnerships among biotech firms and research institutions are recommended to accelerate innovation and market penetration.

However, the market faces several limitations, including high treatment costs, regulatory challenges in therapy approvals, and limited patient populations affecting commercial viability. The complexity of Fabry Disease and its varied manifestations also pose challenges in developing universally effective treatments. Despite this, innovation can thrive through collaborative research in gene editing techniques and exploring novel biomarkers for early intervention.

Emphasis on creating affordable treatment options through biosimilars and generics can capture emerging markets and expand access. The market is also characterized by a competitive landscape with significant investment from pharmaceutical giants and specialized firms alike. Fostering innovation and ensuring regulatory compliance while remaining cost-effective are crucial for sustained growth in the Fabry Disease treatment market.

Understanding Market Dynamics in the Fabry Disease Treatment Market

The Fabry Disease Treatment Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • An increase in orphan drug designations is attracting investments and expediting approval for new therapies.
    • Advancements in enzyme replacement therapies are improving patient outcomes and boosting market growth.
    • Increased awareness and education campaigns are driving demand for early diagnosis and treatment.
  • Market Restraints
    • Challenges in achieving wide-scale adoption of Fabry disease treatments due to high costs
    • Limited number of clinical trials affects the availability of varied and effective treatment options
    • Potential side effects and uncertainties regarding long-term efficacy affect treatment adoption
  • Market Opportunities
    • Exploring strategic partnerships with rare disease organizations for policy advocacy and funding
    • Investing in patient education platforms to enhance understanding of Fabry disease treatment options
    • Collaborating with genetic testing companies to increase early diagnosis and patient outreach
  • Market Challenges
    • Facilitating collaboration and partnership between academia, industry, and patient organizations
    • Mitigating the competitive pressure from emerging and existing Fabry disease treatments
    • Targeting the small and dispersed patient population of Fabry disease internationally

Exploring Porter’s Five Forces for the Fabry Disease Treatment Market

Porter’s Five Forces framework further strengthens the insights of the Fabry Disease Treatment Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Fabry Disease Treatment Market

External macro-environmental factors deeply influence the performance of the Fabry Disease Treatment Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Fabry Disease Treatment Market

The Fabry Disease Treatment Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Fabry Disease Treatment Market

The Fabry Disease Treatment Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Fabry Disease Treatment Market

The Fabry Disease Treatment Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Fabry Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include Amicus Therapeutics Inc., Avrobio Inc., BioMarin, Biosidus S.A., Digestive Care, Inc., GlaxoSmithKline PLC, Idorsia Pharmaceuticals Ltd., ISU Abxis Co Ltd., JCR Pharmaceuticals Co Ltd., Leadiant Biosciences, Inc., Nestle Health Science, Pfizer Inc., Protalix Biotherapeutics Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Fabry Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Treatment Type
    • Enzyme Replacement Therapy
      • Biosimilar and Biobetter Enzymes
      • Recombinant Human α-galactosidase A
    • Gene Therapy
      • CRISPR/Cas9-Based
      • Viral Vector-Based
    • Pharmacological Chaperone Therapy
      • Allosteric Stabilizers
      • Small Molecule Agents
    • Substrate Reduction Therapy
      • Gene Silencing Approaches
      • Glucosylceramide Synthase Inhibitors
  • Disease Domain
    • Cardiac Manifestations
      • Heart Rhythm Management
      • Hypertrophy Management
    • Neurological Manifestations
      • Pain Management
      • Peripheral Neuropathy Therapies
    • Renal Manifestations
      • Dialysis and Renal Replacement
      • Proteinuria Management
  • Patient Age Group
    • Adolescents and Adults
      • Lifestyle Adjustments
      • Symptom Management
    • Infants and Children
      • Developmental Interventions
      • Early Diagnostic Techniques
  • End-User
    • Homecare Settings
      • Home-based Monitoring Devices
      • In-home Therapeutic Solutions
    • Hospitals and Clinics
      • Private Healthcare Facilities
      • Public Healthcare Institutions
    • Research Laboratories
      • Academic Research
      • Commercial R&D
  • Diagnosis and Screening Technology
    • Biomarker Testing
      • Metabolomics-Based
      • Proteomics-Based
    • Genetic Testing
      • Array-Based Analysis
      • Next-Generation Sequencing
  • Treatment Route
    • Intramuscular Administration
      • Needle-Free Solutions
      • Self-Injectables
    • Intravenous Administration
      • Infusion Rate Optimization
      • Portable Infusion Kits
    • Oral Administration
      • Extended Release Formulations
      • Patient-Centric Formulations
  • Cost Analysis
    • Affordability and Accessibility
      • Charity Funded Solutions
      • Subsidized Treatment Programs
    • Cost-Benefit Analysis
      • Insurance Reimbursement
      • Long-term Treatment Costs
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States (California, Florida, Illinois, New York, Ohio, Pennsylvania, Texas)
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  • Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  • Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  • Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  • Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  • Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  • What is the current size of the market, and how is it expected to grow?
  • Which products, segments, and regions present the most attractive investment opportunities?
  • What are the prevailing technology trends and regulatory factors influencing the market?
  • How do top vendors rank regarding market share and competitive positioning?
  • What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. An increase in orphan drug designations is attracting investments and expediting approval for new therapies.
5.1.1.2. Advancements in enzyme replacement therapies are improving patient outcomes and boosting market growth.
5.1.1.3. Increased awareness and education campaigns are driving demand for early diagnosis and treatment.
5.1.2. Restraints
5.1.2.1. Challenges in achieving wide-scale adoption of Fabry disease treatments due to high costs
5.1.2.2. Limited number of clinical trials affects the availability of varied and effective treatment options
5.1.2.3. Potential side effects and uncertainties regarding long-term efficacy affect treatment adoption
5.1.3. Opportunities
5.1.3.1. Exploring strategic partnerships with rare disease organizations for policy advocacy and funding
5.1.3.2. Investing in patient education platforms to enhance understanding of Fabry disease treatment options
5.1.3.3. Collaborating with genetic testing companies to increase early diagnosis and patient outreach
5.1.4. Challenges
5.1.4.1. Facilitating collaboration and partnership between academia, industry, and patient organizations
5.1.4.2. Mitigating the competitive pressure from emerging and existing Fabry disease treatments
5.1.4.3. Targeting the small and dispersed patient population of Fabry disease internationally
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Fabry Disease Treatment Market, by Treatment Type
6.1. Introduction
6.2. Enzyme Replacement Therapy
6.2.1. Biosimilar and Biobetter Enzymes
6.2.2. Recombinant Human a-galactosidase A
6.3. Gene Therapy
6.3.1. CRISPR/Cas9-Based
6.3.2. Viral Vector-Based
6.4. Pharmacological Chaperone Therapy
6.4.1. Allosteric Stabilizers
6.4.2. Small Molecule Agents
6.5. Substrate Reduction Therapy
6.5.1. Gene Silencing Approaches
6.5.2. Glucosylceramide Synthase Inhibitors
7. Fabry Disease Treatment Market, by Disease Domain
7.1. Introduction
7.2. Cardiac Manifestations
7.2.1. Heart Rhythm Management
7.2.2. Hypertrophy Management
7.3. Neurological Manifestations
7.3.1. Pain Management
7.3.2. Peripheral Neuropathy Therapies
7.4. Renal Manifestations
7.4.1. Dialysis and Renal Replacement
7.4.2. Proteinuria Management
8. Fabry Disease Treatment Market, by Patient Age Group
8.1. Introduction
8.2. Adolescents and Adults
8.2.1. Lifestyle Adjustments
8.2.2. Symptom Management
8.3. Infants and Children
8.3.1. Developmental Interventions
8.3.2. Early Diagnostic Techniques
9. Fabry Disease Treatment Market, by End-User
9.1. Introduction
9.2. Homecare Settings
9.2.1. Home-based Monitoring Devices
9.2.2. In-home Therapeutic Solutions
9.3. Hospitals and Clinics
9.3.1. Private Healthcare Facilities
9.3.2. Public Healthcare Institutions
9.4. Research Laboratories
9.4.1. Academic Research
9.4.2. Commercial R&D
10. Fabry Disease Treatment Market, by Diagnosis and Screening Technology
10.1. Introduction
10.2. Biomarker Testing
10.2.1. Metabolomics-Based
10.2.2. Proteomics-Based
10.3. Genetic Testing
10.3.1. Array-Based Analysis
10.3.2. Next-Generation Sequencing
11. Fabry Disease Treatment Market, by Treatment Route
11.1. Introduction
11.2. Intramuscular Administration
11.2.1. Needle-Free Solutions
11.2.2. Self-Injectables
11.3. Intravenous Administration
11.3.1. Infusion Rate Optimization
11.3.2. Portable Infusion Kits
11.4. Oral Administration
11.4.1. Extended Release Formulations
11.4.2. Patient-Centric Formulations
12. Fabry Disease Treatment Market, by Cost Analysis
12.1. Introduction
12.2. Affordability and Accessibility
12.2.1. Charity Funded Solutions
12.2.2. Subsidized Treatment Programs
12.3. Cost-Benefit Analysis
12.3.1. Insurance Reimbursement
12.3.2. Long-term Treatment Costs
13. Americas Fabry Disease Treatment Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific Fabry Disease Treatment Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa Fabry Disease Treatment Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. Market Share Analysis, 2023
16.2. FPNV Positioning Matrix, 2023
16.3. Competitive Scenario Analysis
16.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. FABRY DISEASE TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. FABRY DISEASE TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. FABRY DISEASE TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. FABRY DISEASE TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 5. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY DISEASE DOMAIN, 2023 VS 2030 (%)
FIGURE 11. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY DISEASE DOMAIN, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2030 (%)
FIGURE 13. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 15. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS AND SCREENING TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 17. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS AND SCREENING TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT ROUTE, 2023 VS 2030 (%)
FIGURE 19. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT ROUTE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY COST ANALYSIS, 2023 VS 2030 (%)
FIGURE 21. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY COST ANALYSIS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 25. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 26. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 27. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 30. FABRY DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 31. FABRY DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. FABRY DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. FABRY DISEASE TREATMENT MARKET DYNAMICS
TABLE 7. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY BIOSIMILAR AND BIOBETTER ENZYMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY RECOMBINANT HUMAN ?-GALACTOSIDASE A, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY CRISPR/CAS9-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY VIRAL VECTOR-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY PHARMACOLOGICAL CHAPERONE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ALLOSTERIC STABILIZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY PHARMACOLOGICAL CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY GENE SILENCING APPROACHES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY GLUCOSYLCERAMIDE SYNTHASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY DISEASE DOMAIN, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY CARDIAC MANIFESTATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY HEART RHYTHM MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY HYPERTROPHY MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY CARDIAC MANIFESTATIONS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY NEUROLOGICAL MANIFESTATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY PERIPHERAL NEUROPATHY THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY NEUROLOGICAL MANIFESTATIONS, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY RENAL MANIFESTATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY DIALYSIS AND RENAL REPLACEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY PROTEINURIA MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY RENAL MANIFESTATIONS, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ADOLESCENTS AND ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY LIFESTYLE ADJUSTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY SYMPTOM MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ADOLESCENTS AND ADULTS, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY INFANTS AND CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY DEVELOPMENTAL INTERVENTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY EARLY DIAGNOSTIC TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY INFANTS AND CHILDREN, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY HOME-BASED MONITORING DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY IN-HOME THERAPEUTIC SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY PRIVATE HEALTHCARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY PUBLIC HEALTHCARE INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY COMMERCIAL R&D, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS AND SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY BIOMARKER TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY METABOLOMICS-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY PROTEOMICS-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY BIOMARKER TESTING, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ARRAY-BASED ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT ROUTE, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY INTRAMUSCULAR ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY NEEDLE-FREE SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY SELF-INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY INTRAMUSCULAR ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY INFUSION RATE OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY PORTABLE INFUSION KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY EXTENDED RELEASE FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT-CENTRIC FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY COST ANALYSIS, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY AFFORDABILITY AND ACCESSIBILITY, BY REGION, 2018-2030 (USD MILLION)
TABLE 83. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY CHARITY FUNDED SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 84. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSIDIZED TREATMENT PROGRAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 85. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY AFFORDABILITY AND ACCESSIBILITY, 2018-2030 (USD MILLION)
TABLE 86. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY COST-BENEFIT ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 87. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY INSURANCE REIMBURSEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 88. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY LONG-TERM TREATMENT COSTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 89. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY COST-BENEFIT ANALYSIS, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY PHARMACOLOGICAL CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY DISEASE DOMAIN, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY CARDIAC MANIFESTATIONS, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY NEUROLOGICAL MANIFESTATIONS, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY RENAL MANIFESTATIONS, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY ADOLESCENTS AND ADULTS, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY INFANTS AND CHILDREN, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 103. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 104. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 105. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2030 (USD MILLION)
TABLE 106. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS AND SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 107. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY BIOMARKER TESTING, 2018-2030 (USD MILLION)
TABLE 108. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 109. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT ROUTE, 2018-2030 (USD MILLION)
TABLE 110. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY INTRAMUSCULAR ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY COST ANALYSIS, 2018-2030 (USD MILLION)
TABLE 114. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY AFFORDABILITY AND ACCESSIBILITY, 2018-2030 (USD MILLION)
TABLE 115. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY COST-BENEFIT ANALYSIS, 2018-2030 (USD MILLION)
TABLE 116. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY PHARMACOLOGICAL CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY DISEASE DOMAIN, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY CARDIAC MANIFESTATIONS, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY NEUROLOGICAL MANIFESTATIONS, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY RENAL MANIFESTATIONS, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY ADOLESCENTS AND ADULTS, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY INFANTS AND CHILDREN, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS AND SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY BIOMARKER TESTING, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT ROUTE, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY INTRAMUSCULAR ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY COST ANALYSIS, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY AFFORDABILITY AND ACCESSIBILITY, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY COST-BENEFIT ANALYSIS, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY PHARMACOLOGICAL CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY DISEASE DOMAIN, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY CARDIAC MANIFESTATIONS, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY NEUROLOGICAL MANIFESTATIONS, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY RENAL MANIFESTATIONS, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY ADOLESCENTS AND ADULTS, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY INFANTS AND CHILDREN, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 157. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 158. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2030 (USD MILLION)
TABLE 159. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS AND SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 160. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY BIOMARKER TESTING, 2018-2030 (USD MILLION)
TABLE 161. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 162. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT ROUTE, 2018-2030 (USD MILLION)
TABLE 163. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY INTRAMUSCULAR ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 166. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY COST ANALYSIS, 2018-2030 (USD MILLION)
TABLE 167. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY AFFORDABILITY AND ACCESSIBILITY, 2018-2030 (USD MILLION)
TABLE 168. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY COST-BENEFIT ANALYSIS, 2018-2030 (USD MILLION)
TABLE 169. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 170. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 171. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 172. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY PHARMACOLOGICAL CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 173. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 174. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY DISEASE DOMAIN, 2018-2030 (USD MILLION)
TABLE 175. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY CARDIAC MANIFESTATIONS, 2018-2030 (USD MILLION)
TABLE 176. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY NEUROLOGICAL MANIFESTATIONS, 2018-2030 (USD MILLION)
TABLE 177. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY RENAL MANIFESTATIONS, 2018-2030 (USD MILLION)
TABLE 178. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 179. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY ADOLESCENTS AND ADULTS, 2018-2030 (USD MILLION)
TABLE 180. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY INFANTS AND CHILDREN, 2018-2030 (USD MILLION)
TABLE 181. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 182. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 183. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 184. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2030 (USD MILLION)
TABLE 185. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS AND SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 186. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY BIOMARKER TESTING, 2018-2030 (USD MILLION)
TABLE 187. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 188. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT ROUTE, 2018-2030 (USD MILLION)
TABLE 189. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY INTRAMUSCULAR ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 191. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY COST ANALYSIS, 2018-2030 (USD MILLION)
TABLE 193. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY AFFORDABILITY AND ACCESSIBILITY, 2018-2030 (USD MILLION)
TABLE 194. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY COST-BENEFIT ANALYSIS, 2018-2030 (USD MILLION)
TABLE 195. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 196. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 197. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 198. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY PHARMACOLOGICAL CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 199. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 200. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY DISEASE DOMAIN, 2018-2030 (USD MILLION)
TABLE 201. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY CARDIAC MANIFESTATIONS, 2018-2030 (USD MILLION)
TABLE 202. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY NEUROLOGICAL MANIFESTATIONS, 2018-2030 (USD MILLION)
TABLE 203. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY RENAL MANIFESTATIONS, 2018-2030 (USD MILLION)
TABLE 204. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 205. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY ADOLESCENTS AND ADULTS, 2018-2030 (USD MILLION)
TABLE 206. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY INFANTS AND CHILDREN, 2018-2030 (USD MILLION)
TABLE 207. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 208. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 209. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 210. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2030 (USD MILLION)
TABLE 211. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS AND SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 212. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY BIOMARKER TESTING, 2018-2030 (USD MILLION)
TABLE 213. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 214. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT ROUTE, 2018-2030 (USD MILLION)
TABLE 215. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY INTRAMUSCULAR ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 216. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 217. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 218. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY COST ANALYSIS, 2018-2030 (USD MILLION)
TABLE 219. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY AFFORDABILITY AND ACCESSIBILITY, 2018-2030 (USD MILLION)
TABLE 220. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY COST-BENEFIT ANALYSIS, 2018-2030 (USD MILLION)
TABLE 221. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 222. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 223. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 224. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY PHARMACOLOGICAL CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 225. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 226. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY DISEASE DOMAIN, 2018-2030 (USD MILLION)
TABLE 227. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY CARDIAC MANIFESTATIONS, 2018-2030 (USD MILLION)
TABLE 228. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY NEUROLOGICAL MANIFESTATIONS, 2018-2030 (USD MILLION)
TABLE 229. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY RENAL MANIFESTATIONS, 2018-2030 (USD MILLION)
TABLE 230. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 231. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY ADOLESCENTS AND ADULTS, 2018-2030 (USD MILLION)
TABLE 232. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY INFANTS AND CHILDREN, 2018-2030 (USD MILLION)
TABLE 233. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 234. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 235. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 236. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2030 (USD MILLION)
TABLE 237. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS AND SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 238. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY BIOMARKER TESTING, 2018-2030 (USD MILLION)
TABLE 239. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 240. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT ROUTE, 2018-2030 (USD MILLION)
TABLE 241. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY INTRAMUSCULAR ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 242. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 243. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY COST ANALYSIS, 2018-2030 (USD MILLION)
TABLE 245. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY AFFORDABILITY AND ACCESSIBILITY, 2018-2030 (USD MILLION)
TABLE 246. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY COST-BENEFIT ANALYSIS, 2018-2030 (USD MILLION)
TABLE 247. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 248. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 249. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 250. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 251. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY PHARMACOLOGICAL CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 252. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 253. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY DISEASE DOMAIN, 2018-2030 (USD MILLION)
TABLE 254. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY CARDIAC MANIFESTATIONS, 2018-2030 (USD MILLION)
TABLE 255. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY NEUROLOGICAL MANIFESTATIONS, 2018-2030 (USD MILLION)
TABLE 256. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY RENAL MANIFESTATIONS, 2018-2030 (USD MILLION)
TABLE 257. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 258. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY ADOLESCENTS AND ADULTS, 2018-2030 (USD MILLION)
TABLE 259. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY INFANTS AND CHILDREN, 2018-2030 (USD MILLION)
TABLE 260. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 261. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 262. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 263. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2030 (USD MILLION)
TABLE 264. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS AND SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY BIOMARKER TESTING, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT ROUTE, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY INTRAMUSCULAR ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY COST ANALYSIS, 2018-2030 (USD MILLION)
TABLE 272. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY AFFORDABILITY AND ACCESSIBILITY, 2018-2030 (USD MILLION)
TABLE 273. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY COST-BENEFIT ANALYSIS, 2018-2030 (USD MILLION)
TABLE 274. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 275. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 276. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 277. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 278. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY PHARMACOLOGICAL CHAPERONE THERAPY, 2018-2030 (USD MILLION)
TABLE 279. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 280. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY DISEASE DOMAIN, 2018-2030 (USD MILLION)
TABLE 281. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY CARDIAC MANIFESTATIONS, 2018-2030 (USD MILLION)
TABLE 282. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY NEUROLOGICAL MANIFESTATIONS, 2018-2030 (USD MILLION)
TABLE 283. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY RENAL MANIFESTATIONS, 2018-2030 (USD MILLION)
TABLE 284. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 285. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY ADOLESCENTS AND ADULTS, 2018-2030 (USD MILLION)
TABLE 286. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY INFANTS AND CHILDREN, 2018-2030 (USD MILLION)
TABLE 287. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 288. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 289. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 290. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2030 (USD MILLION)
TABLE 291. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS AND SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 292. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY BIOMARKER TESTING, 2018-2030 (USD MILLION)
TABLE 293. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 294. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT ROUTE, 2018-2030 (USD MILLION)
TABLE 295. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY INTRAMUSCULAR ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 296. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 297. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 298. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY COST ANALYSIS, 2018-2030 (USD MILLION)
TABLE 299. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY AFFORDABILITY AND ACCESSIBILITY, 2018-2030 (USD MILLION)
TABLE 300. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY COST-BENEFIT ANALYSIS, 2018-2030 (USD MILLION)
TABLE 301. CHINA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 302. CHINA FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 303. CHINA FABRY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 304. CHINA FABRY DISEASE TREATM

Companies Mentioned

  • Amicus Therapeutics Inc.
  • Avrobio Inc.
  • BioMarin
  • Biosidus S.A.
  • Digestive Care, Inc.
  • GlaxoSmithKline PLC
  • Idorsia Pharmaceuticals Ltd.
  • ISU Abxis Co Ltd.
  • JCR Pharmaceuticals Co Ltd.
  • Leadiant Biosciences, Inc.
  • Nestle Health Science
  • Pfizer Inc.
  • Protalix Biotherapeutics Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages182
PublishedNovember 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 2.71 billion
Forecasted Market Value ( USD ) by 2030 $ 4.41 billion
Compound Annual Growth Rate8.4%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Fabry Disease Treatment Market Size, Share & Trends Analysis Report By Solution, By Treatment (Enzyme Replacement Therapy), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Fabry Disease Treatment Market Size, Share & Trends Analysis Report By Solution, By Treatment (Enzyme Replacement Therapy), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 100 Pages
  • Global
From
Fabry Disease Treatment Global Market Report 2024 - Product Image

Fabry Disease Treatment Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Fabry Disease Market Report by Type (Type 1, Type 2, and Others), Diagnosis and Treatment (Diagnosis, Treatment), End User (Hospitals, Homecare, Specialty Clinics, and Others), and Region 2024-2032 - Product Image

Fabry Disease Market Report by Type (Type 1, Type 2, and Others), Diagnosis and Treatment (Diagnosis, Treatment), End User (Hospitals, Homecare, Specialty Clinics, and Others), and Region 2024-2032

  • Report
  • 148 Pages
  • Global
From
Fabry Disease Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Fabry Disease Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 106 Pages
  • Global
From
Fabry Disease Drugs Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Product Type - Product Image

Fabry Disease Drugs Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Product Type

  • Report
  • 90 Pages
  • Global
From

About the Fabry Disease Drug Market

Fabry Disease is a rare, inherited disorder caused by the deficiency of an enzyme called alpha-galactosidase A. This deficiency leads to the accumulation of a fatty substance called globotriaosylceramide (GL-3) in the body's cells, resulting in a wide range of symptoms. Endocrine and Metabolic Disorders Drugs are used to treat Fabry Disease, including enzyme replacement therapy (ERT) and chaperone therapy. ERT is the most common treatment, and involves the administration of a recombinant form of the missing enzyme. Chaperone therapy is a newer treatment option, and involves the use of small molecules to help the body's cells process GL-3. The Fabry Disease Drug market is a rapidly growing segment of the Endocrine and Metabolic Disorders Drugs market. Companies in the market include Sanofi, Amicus Therapeutics, Shire, and Pfizer. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.